Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
  • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
  • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
  • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
  • A61K2039/507—Comprising a combination of two or more separate antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/80—Vaccine for a specifically defined cancer
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/80—Vaccine for a specifically defined cancer
  • A61K2039/82—Colon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Definitions

• This disclosure relates to a monoclonal antibody directed against anti-cluster differentiation [CD]73 (CD73) or an antigen-binding fragment thereof, and the use of such antibody or antigen-binding fragment thereof in the treatment of tumors.
• the disclosure also relates to methods for the treatment of tumors comprising administering to a patient in need thereof an anti-CD73 antibody or antigen-binding fragment thereof in combination with a monoclonal antibody directed against programmed death-ligand l(PD-Ll) also known as B7 homolog 1 (B7-H1), or an antigen-binding fragment thereof.
• PD-Ll programmed death-ligand l
• B7-H1 B7 homolog 1
• the disclosure also relates to methods for the treatment of tumors comprising administering to a patient in need thereof an anti-CD73 antibody or antigen-binding fragment thereof in combination with a PD-L1 antibody or an antigen-binding fragment thereof and/or chemotherapy.
• CD73 or ecto-5'-nucleotidase (5'-NT) is ubiquitously expressed in a number of tissues. This protein is anchored to the cell membrane through a glycosylphosphatidylinositol (GPI) linkage, has ecto-enzyme activity, and plays a role in signal transduction.
• GPI glycosylphosphatidylinositol
• the primary function of CD73 is the conversion of extracellular nucleotides (e.g., 5'-AMP), to which cells are generally impermeable, to their corresponding nucleosides (e.g., adenosine), which can readily enter most cells.
• CD73 production of adenosine by the dephosphorylation of AMP has been shown to regulate adenosine receptor engagement in many tissues, indicating that adenosine functions in cytoprotection, cell growth, angiogenesis and immunosuppression, and also plays a role in tumorigenesis.
• CD73 expression on tumor cells has been reported in several types of cancer, including colorectal cancer, pancreatic cancer, bladder cancer, leukemia, lymphoma, glioma, glioblastoma, melanoma, ovarian cancer, thyroid cancer, esophageal cancer, prostate cancer, and breast cancer. Elevated CD73 expression has also been associated with tumor invasiveness, metastasis, and reduced patient survival time. CD73 generates an immunosuppressed
• CD73 expression has been associated with a prometastatic phenotype in melanoma and breast cancer.
• Programmed death-ligand l(PD-Ll), also known as B7H1 is a 40 kDa transmembrane protein that is a major obstacle in anti-cancer immunity.
• PD-L1 binding to the programmed death receptor (PD-1) inactivates T-cells, protects tumor cells, and suppresses immune system detection, allowing for unchecked proliferation of cancer cells.
• PD-L1 also binds CD80, a co stimulatory molecule.
• a wide range of tumorigenic and activated immune cell types naturally express PD-L1, including antigen presenting cells, macrophages, monocytes, B cells, T cells and non-hematopoietic cells.
• inflammatory cytokines induce PD-L1 expression; including interferon gamma (IF Ng ) .
• IF Ng interferon gamma
• Activated T-cells produced IFNy, the most potent inducer of PD-L1.
• IFNy in turn induces PD-L1 expression, promoting tumor protection, a mechanism known as adaptive immune resistance.
• the disclosure provides a method of treating a tumor in a human patient, comprising administering oleclumab or antigen-binding fragment thereof to the patient.
• oleclumab or antigen-binding fragment thereof is administered at a dose of 750- 3000 mg.
• oleclumab or antigen-binding fragment thereof is administered at a dose of 40 mg/kg.
• the disclosure further provides a method of treating a tumor in a human patient, comprising administering oleclumab or antigen-binding fragment thereof and durvalumab or antigen-binding fragment thereof to the patient.
• the disclosure further provides a method of treating a tumor in a human patient, comprising administering oleclumab or antigen-binding fragment thereof and chemotherapy to the patient.
• a method of treating a tumor in a human patient comprises administering oleclumab or antigen-binding fragment thereof to the patient.
• a method of treating a tumor in a human patient comprises administering oleclumab or antigen-binding fragment thereof and durvalumab or antigen-binding fragment thereof to the patient.
• a method treating a tumor in a human patient comprises
• the method further comprises administering durvalumab or antigen-binding fragment thereof.
• the oleclumab or antigen-binding fragment thereof is administered at a dose of 750 mg to 3000 mg. In some aspects, the oleclumab or antigen-binding fragment thereof is administered at a dose of 750 mg. In some aspects, the oleclumab or antigen-binding fragment thereof is administered at a dose of 1500 mg. In some aspects, the oleclumab or antigen-binding fragment thereof is administered at a dose of 2250 mg. In some aspects, the oleclumab or antigen-binding fragment thereof is administered at a dose of 3000 mg.
• the oleclumab or antigen-binding fragment thereof is administered at a dose of 2250 mg and then at a dose of 3000 mg. In some aspects, the oleclumab or antigen-binding fragment thereof is administered at a dose of 2250 mg for four doses and then at a dose of 3000 mg.
• the oleclumab or antigen-binding fragment thereof is administered every 14 to 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered every 14 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered every 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered every 14 days for at least two doses and then every 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered every 14 days for four doses and then every 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered every 21 days.
• the oleclumab or antigen-binding fragment thereof is administered every 21 days for at least two doses and then every 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered every 21 days for two to four doses and then every 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered every 21 days for two doses and then once every 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered once every 21 days for four doses and then once every 28 days.
• the oleclumab or antigen-binding fragment thereof is administered at a dose of 2250 mg once every 21 days for two doses and then at a dose of 3000 mg once every 28 days. In some aspects, the oleclumab or antigen-binding fragment thereof is administered at a dose of 2250 mg once every 21 days for four doses and then at a dose of 3000 mg once every 28 days.
• the oleclumab or antigen-binding fragment thereof is administered intravenously.
• the durvalumab or antigen-binding fragment thereof is administered at a dose of 1500 mg.
• the durvalumab or antigen-binding fragment thereof is administered every 21 days to every 28 days. In some aspects, the durvalumab or antigen-binding fragment thereof is administered every 28 days. In some aspects, the durvalumab or antigen-binding fragment thereof is administered every 21 days. In some aspects, the durvalumab or antigen binding fragment thereof is administered every 21 days for at least two doses and then every 28 days. In some aspects, the durvalumab or antigen-binding fragment thereof is administered every 21 days for four doses and then every 28 days.
• the durvalumab or antigen-binding fragment thereof is administered at a dose of 1500 mg every 21 days for four doses and then at a dose of 1500 mg every 28 days.
• the durvalumab or antigen-binding fragment thereof is administered intravenously.
• the chemotherapy comprises at least one of cisplatin, pemetrexed. nab-paclitaxel, carhop latin, gemcitabine, cisplatin, oxaliplatin, leucovorin, 5-fluorouracil, and docetaxel.
• the chemotherapy comprises oxaliplatin, leucovorin, and 5- fluorouracil.
• the oxaliplatin is administered at a dose of 85 mg/m 2 . In some aspects, the oxaliplatin is administered every 2 weeks. [0024] In some aspects, the leucovorin is administered at a dose of 400 mg/m 2 . In some aspects, the leucovorin is administered every 2 weeks.
• the 5-fluorouracil is administered at a dose of 2400 mg/m 2 . In some aspects, the 5-fluorouracil is administered by continuous intravenous infusion for 46 to 48 hours. In some aspects, the 5-fluorouracil is administered over 46 to 48 hours every 2 weeks.
• the chemotherapy comprises 85 mg/m 2 oxaliplatin, 400 mg/m 2 leucovorin and 2400 mg/m 2 5-fluorouracil.
• the method further comprises administering bevacizumab or an antigen-binding fragment thereof.
• the bevacizumab or an antigen-binding fragment thereof is administered at a dose of 5 mg/kg.
• the bevacizumab or an antigen-binding fragment thereof is administered every 2 weeks.
• the bevacizumab or an antigen-binding fragment thereof is administered intravenously.
• the chemotherapy comprises (a) nab-paclitaxel and carboplatin; (b) gemcitabine and cisplatin; (c) gemcitabine and carboplatin; (d) pemetrexed and carboplatin; and (e) pemetrexed and cisplatin.
• the nab-paclitaxel is administered at a dose of 100 mg/m 2 . In some aspects, the nab-paclitaxel is administered on days 1, 8, and 15 of a 21 -day cycle.
• the gemcitabine is administered at a dose of 1000 mg/m 2 or 1250 mg/m 2 . In some aspects, the gemcitabine is administered on days 1 and 8 of a 21 -day cycle.
• the pemetrexed is administered at a dose of 500 mg/m 2 . In some aspects, the pemetrexed is administered every three weeks.
• the carboplatin is administered at a dose of AUC 5 or 6. In some aspects, the carboplatin is administered every three weeks.
• the cisplatin is administered at a dose of 75 mg/m 2 . In some aspects, the cisplatin is administered every three weeks.
• the chemotherapy comprises 1000 mg/m 2 gemcitabine and 125 mg/m 2 nab-paclitaxel.
• the chemotherapy is administered every 7 days to 28 days. In some aspects, the chemotherapy is administered every 14 days. [0036] In some aspects, the administration of oleclumab or antigen-binding fragment thereof results in a partial response. In some aspects, the administration of oleclumab or antigen-binding fragment thereof results in a complete response.
• the tumor is a solid tumor.
• the solid tumor is breast cancer, ovarian cancer, head and neck cancer, prostate cancer, bladder cancer, colorectal cancer, non-small cell lung cancer (NSCLC), glioblastoma, renal cell cancer, or pancreatic cancer.
• the pancreatic cancer is pancreatic ductal adenocarcinoma.
• the tumor is a resectable NSCLC tumor.
• the tumor is an early-stage NSCLC tumor.
• the tumor is stage IV NSCLC tumor.
• the colorectal cancer is metastatic microsatellite-stable.
• the tumor has high-PD-Ll expression.
• the tumor with high-PD-Ll expression can be a NSCLC tumor.
• the tumor has low-PD-Ll expression.
• the tumor with low-PD-Ll expression can be a NSCLC tumor.
• the tumor lacks an activating epidermal growth factor receptor (EGFR) mutation and/or an anaplastic lymphoma kinase (ALK) fusion.
• EGFR epidermal growth factor receptor
• ALK anaplastic lymphoma kinase
• the tumor that lacks an EGFR mutation and/or an ALK fusion can be a NSCLC tumor.
• the patient has metastatic pancreatic ductal adenocarcinoma that has not been previously treated. In some aspects, the patient has metastatic pancreatic ductal adenocarcinoma that was previously treated with gemcitabine-based therapy.
• the tumor has not received prior treatment in the recurrent and/or metastatic setting.
• the patient has progressed on an anti -PD- 1 or anti-PD-Ll containing therapy.
• the tumor is a 1 st line metastatic pancreatic ductal adenocarcinoma, wherein the oleclumab or antigen binding fragment thereof is administered at 1500 mg or 3000 mg every 2 weeks for four doses and then every 4 weeks, and wherein the chemotherapy comprises 1000 mg/m 2 gemcitabine and 125 mg/m 2 nab-paclitaxel, wherein the chemotherapy is administered on days 1, 8, and 15 of four 28-day cycles and then every 4 weeks.
• the tumor is a 2 nd line metastatic pancreatic ductal adenocarcinoma
• the oleclumab or antigen binding fragment thereof is administered at 1500 mg or 3000 mg every 2 weeks for four doses and then every 4 weeks
• the chemotherapy comprises 85 mg/m 2 oxaliplatin, 400 mg/m 2 leucovorin, and 400 mg/m 2 5-FU followed by 2400 mg/m 2 5-FU, wherein the chemotherapy is administered on days 1 and 15 of four 28-day cycles and then every 4 weeks.
• the method further comprises administering 1500 mg durvalumab or an antigen-binding fragment thereof every 4 weeks.
• the tumor is a 1 st line stage IV NSCLC with high PD-L1 expression, wherein the oleclumab or antigen binding fragment thereof is administered at 1500 mg or 3000 mg every 2 weeks for two 14-day cycles and then every 4 weeks, and wherein the durvalumab or an antigen-binding fragment thereof is administered at 1500 mg every 4 weeks.
• the tumor is a 1 st line stage IV NSCLC with low PD-L1 expression, wherein the oleclumab or antigen binding fragment thereof is administered (a) at 1500 mg every 3 weeks for four 21 -day cycles and then every 4 weeks; or (b) at 2250 mg every 3 weeks for four 21 -day cycles and then at 3000 mg every 4 weeks; the durvalumab or antigen binding fragment thereof is administered at 1500 mg every 3 weeks for four 21 -day cycles and then every 4 weeks; and the chemotherapy comprises: (a) 100 mg/m 2 nab-paclitaxel on days 1, 8, and 15 of a 21 -day cycle for 4 cycles and 5 or 6 AUC carboplatin on day 1 of the 21 -day cycle for 4 cycles; (b) 1000 mg/m 2 or 1250 mg/m 2 gemcitabine on days 1 and 8 of a 21 -day cycle for 4 cycles and 75 mg/m 2 cisplatin on day 1 of the 21 -day cycle for 4 cycles;
• the tumor is a locally advanced, unresectable, stage III NSCLC tumor, and wherein (i) 1500 mg durvalumab or an antigen-binding fragment thereof is administered every 4 weeks and (ii) 3000 mg oleclumab or an antigen-binding fragment thereof is administered every 2 weeks for 2 months and then every 4 weeks. [0049] In some aspects, the tumor is a resectable, early NSCLC tumor, and wherein (i) 1500 mg durvalumab or an antigen-binding fragment thereof is administered and (ii) 3000 mg oleclumab or an antigen-binding fragment thereof is administered every 2 weeks.
• the tumor is a metastatic microsatellite-stable colorectal cancer tumor, and wherein (i) 1500 mg durvalumab or an antigen-binding fragment thereof is administered every 4 weeks; (ii) 3000 mg oleclumab or an antigen-binding fragment thereof is administered every 2 weeks for four doses and then every 4 weeks; (iii) the chemotherapy comprises (a) 400 mg/m 2 of folinic acid every 2 weeks (b) 85 mg/m 2 oxaliplatin every 2 weeks; and (c) 2400 mg/m 2 of 5-fluorouracil every 2 weeks; and (iv) 5 mg/kg of bevacizumab or an antigen-binding fragment thereof is administered every 2 weeks.
• the tumor is a microsatellite-stable colorectal cancer tumor, and wherein (i) 1500 mg durvalumab or an antigen-binding fragment thereof is administered every 4 weeks; (ii) 3000 mg oleclumab or an antigen-binding fragment thereof is administered every 2 weeks for four or five doses and then every 4 weeks; and (iii) the chemotherapy comprises (a) 400 mg/m 2 of folinic acid every 2 weeks (b) 85 mg/m 2 oxaliplatin every 2 weeks; and (c) 400 mg/m 2 of 5-fluorouracil on day 1 and then 2400 mg/m 2 of 5-fluorouracil every 2 weeks.
• the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• ECG Eastern Cooperative Oncology Group
• Fig. 1 is a graph demonstrating the concentration of free sCD73 in cynomolgus monkeys administered a dose of 0 mg/kg (Group 1), 1 mg/kg (Group 2), 10 mg/kg (Group 3) or 107.8 mg/kg (Group 4) of oleclumab. (See Example 2.)
• Figs. 2A and 2B show that oleclumab administration did not enhance key hole limpet hemocyanin T-dependent Antibody Response (KLH TDAR) in a dose-dependent manner.
• Fig. 2A shows the mean anti-KLH IgM titers following KLH immunization in monkeys administered a dose of 0 mg/kg, 1 mg/kg, 10 mg/kg or 107.8 mg/kg of oleclumab
• Fig. 2B shows the mean anti-KLH IgG titers following KLH immunization in monkeys administered a dose of 0 mg/kg, 1 mg/kg, 10 mg/kg or 107.8 mg/kg of oleclumab. (See Example 2.)
• Figs. 3A and 3B show that oleclumab administration did not increase ex vivo IFN-g or IL-2 production following KLH stimulation of peripheral blood mononuclear cells.
• Fig. 3A shows the mean KLH specific IFN-g production following KLH immunization in monkeys administered a dose of 0 mg/kg, 1 mg/kg, 10 mg/kg or 107.8 mg/kg of oleclumab
• Fig. 3B shows the KLH specific IL-2 production following KLH immunization in monkeys administered a dose of 0 mg/kg, 1 mg/kg, 10 mg/kg or 107.8 mg/kg of oleclumab. (See Example 2.)
• Fig. 4 shows that lymphocryptovirus (LCV) was detected by qPCR in most samples obtained from monkeys administered a dose of 0 mg/kg, 1 mg/kg, 10 mg/kg or 107.8 mg/kg of oleclumab. (See Example 2.)
• Fig. 5 shows model assumptions for a pharmacokinetic/pharmacodynamic model for use in the prediction of therapeutic human doses of oleclumab.
• a two-compartment model with linear and target-mediated drug disposition clearance was used to adequately describe the MEDI9447 serum concentration profiles. This model was used to describe the monkey pharmacokinetic data and then resulting parameters were allometrically scaled to humans to predict doses using simulation. (See Example 2.)
• Figs. 6A and 6B show cynomolgus pharmacokinetic modeling and human dose prediction. Cynomolgus serum MEDI9447 concentration profiles (Fig. 6A) were described adequately all three different dose levels by a non-linear model shown schematically in ( Figure 5). Following allometric scaling of the pharmacokinetics parameters from this model, human serum concentration profiles were simulated (Fig. 6B). A serum exposure target of 52 pg/mL was determined from the tumor suppression data in syngeneic mice and simulations suggested that doses equal to or higher than 15 mg/kg given every two weeks (Q2W) would attain and maintain adequate exposure during the entire dosing period that are expected to result in efficacy. (See Example 2.)
• Figs. 7A and 7B show the study flow diagram for the dose escalation phase for oleclumab monotherapy arm (pancreatic cancer and microsatellite stable colorectal cancer (MSS-CRC)).
• Fig. 7B shows the study flow diagram for the dose-expansion and dose- escalation portions of the study administering oleclumab (MEDI9447) and durvalumab as combination therapy to human patients with advanced solid tumors (pancreatic cancer and MSS- CRC). (See Example 3.)
• Fig. 8 shows the dosing schema for the screening, treatment, and follow-up periods of the study administering oleclumab (MEDI9447) as a monotherapy and oleclumab (MEDI9447) /durvalumab combination therapy to human patients.
• Figs. 9A and 9B show the amount of free soluble CD73 observed following administration of oleclumab either as a monotherapy (Fig. 9A) or in combination therapy with Durvalumab (Fig. 9B).
• sCD73, soluble CD73; PD LLOQ lower limit of quantification.
• Figs. 10A-C show oleclumab decreased CD73 on peripheral T cells and tumor CD73 surface expression as measured by mean fluorescence intensity (MFI) (Fig. 10A) and percent CD73 + CD4 and CD8 cells; (Fig. 10B) in peripheral blood across all doses after administration of oleclumab; and (Fig. IOC) in peripheral T cells. SSC; side scatter. (See Example 3.)
• Figs. 11A-C show the change in the percentage of CD73 staining tumor cells at a 2+ or 3+ intensity by immunohistochemistry 20 days after oleclumab administration at 10, 20 or 40 mg/kg in either pancreatic or colorectal cancer (CRC) subjects.
• Fig. 11B shows CD73 staining on tumors pre and post treatment with oleclumab.
• Fig. 11C shows the change in CD73 staining tumor cells at a 2+ or 3+ staining intensity and the change in CD8 TILs 20 days after oleclumab administration at 10, 20 or 40 mg/kg relative to baseline. (See Example 3.)
• Fig. 12 shows that Oleclumab inhibited CD73 enzymatic activity in tumor microenvironment. Staining shows a decrease in free adenosine. (See Example 3.)
• Figs. 14A and 14B show that oleclumab demonstrated evidence of PD effect.
• Fig. 14A shows the change in percentage of tumor.
• Fig. 14B shows the change in CD8 TILs. (See Example 3.)
• Fig. 15 shows the dose expansion phase for oleclumab in combination with durvalumab. (See Example 4.)
• Fig. 16 shows the clinical activity of oleclumab in combination with durvalumab in MSS-CRC. Ongoing treatment for > 600 days. (See Example 4.)
• Fig. 17 shows the clinical activity of oleclumab in combination with durvalumab in pancreatic cancer. (See Example 4.)
• Fig. 18 shows the clinical activity of oleclumab in combination with durvalumab in EGFRm NSCLC.
• Fig. 19 shows the study flow diagram for the dose escalation phase for oleclumab in combination with durvalumab and chemotherapy (gemcitabine + nab-paclitaxel for subjects with 1L metastatic PD AC [Cohort A]; mFOLFOX for subjects with 2L metastatic PD AC [Cohort B]). (See Example 5.)
• Fig. 20 shows the treatment regimen for the dose escalation phase for oleclumab in combination with durvalumab and chemotherapy (gemcitabine + nab-paclitaxel for subjects with 1L metastatic PD AC [Cohort A]; mFOLFOX for subjects with 2L metastatic PD AC [Cohort B]). (See Example 5.)
• Fig. 21 shows the study flow diagram for the dose expansion phase for oleclumab in combination with durvalumab and chemotherapy. (See Example 5.)
• Fig. 22 shows the treatment regimen for the dose expansion phase for oleclumab in combination with durvalumab and chemotherapy (gemcitabine + nab-paclitaxel for subjects with 1L metastatic PDAC [Cohort A] (See Example 5.)
• Fig. 23 shows the treatment regimen for the dose expansion phase for oleclumab in combination with durvalumab and chemotherapy mFOLFOX for subjects with 2L metastatic PDAC [Cohort B] (See Example 5.)
• Figs. 24A-D show treatment regimens for patients with first-line Stage IV non-small cell lung cancer (NSCLC).
• Fig. 24A shows the durvalumab monotherapy dosing schedule.
• Fig. 24B shows the durvalumab + oleclumab dosing schedule.
• Fig. 24C shows the durvalumab + chemotherapy dosing schedule.
• Fig. 24D shows the durvalumab + chemotherapy + oleclumab dosing schedule. (See Example 6.)
• Figs. 25A-B show treatment regimens for locally advanced, unresectable, Stage III non-small cell lung cancer (NSCLC).
• Fig. 25A shows the durvalumab monotherapy dosing schedule.
• D durvalumab;
• a subjects receive durvalumab 1500 mg intravenous (IV) every 4 weeks (Q4W) on Day 1 of each cycle.
• Fig. 25B shows the durvalumab + oleclumab dosing schedule.
• Figs. 26A-C show treatment regimens for resectable, early-stage non-small cell lung cancer (NSCLC).
• Fig. 26A shows the treatment over the course of the study duration.
• Fig. 27 shows treatment regimens for metastatic microsatellite-stable colorectal cancer.
• DLT dose-limiting toxicity
• FOLFOX folinic acid (leucovorin), 5-flurouracil, oxaliplatin.
• Subjects in Control 1 receive FOFFOX plus bevacizumab.
• Subjects in Arms SI and El also receive durvalumab 1500 mg intravenous (IV) every 4 weeks (Q4W) on Day 1 of every other 14-day cycle, and oleclumab 3000 mg IV every 2 weeks (Q2W) x 4 doses starting Cycle 1, Day 1, then Q4W starting on Cycle 5, Day 1.
• oleclumab is administered first.
• Fig. 28 shows treatment regimens for high risk metastatic microsatellite-stable colorectal cancer.
• mFOLFOX6 folinic acid (leucovorin), 5-fluorouracil, oxaliplatin.
• Subjects in the Control Arm receive mFOLFOX6.
• Subjects in Arm El-COC receive mFOLFOX6 plus durvalumab 1500 mg intravenous (IV) every 4 weeks (Q4W).
• Subjects in Arm E2 receive mFOLFOX6 plus durvalumab 1500 mg IV Q4W and oleclumab 300 mg IV every 2 weeks (Q2W) for four doses then Q4W starting Cycle 5 (Week 9, Day 1).
• Figs. 29A-I show individual tumor growth (CT26) post-treatment with a combination of anti-CD73, anti-PD-Ll, 5FU, and OHP.
• Fig. 291 shows a Kaplan-Meier (survival curve) of CT26 tumor-bearing B ALB/c mice post treatment with a combination of anti- CD73, anti-PD-Ll, 5FU and OHP. (See Example 11.)
• Fig. 30 shows an increase in IFNy+ CD8+, CD4+ and NKp46+ lymphocytes in the tumor microenvironment (TME) of CT26 tumor-bearing BALB/c mice post-treatment with a combination of anti-CD73, anti-PD-Ll, 5FU, and OHP. (See Example 11.)
• Figs. 31A-I show the individual tumor growth (CT26) post-treatment with a combination of anti-CD73, anti-PD-Ll, and docetaxel.
• Fig. 311 shows a Kaplan-Meier (survival curve) of CT26 tumor-bearing B ALB/c mice post-treatment with a combination of anti- CD73, anti-PD-Ll, and docetaxel. (See Example 11.)
• Figs. 32A-H show the individual tumor growth profiles of MCA205 tumor-bearing C57BL/6 mice post-treatment with a combination of anti-CD73, anti-PD-Ll, 5FU, and OHP.
• This disclosure relates to a monoclonal antibody directed against CD73, such as oleclumab, or an antigen-binding fragment thereof, and the use of such antibody or antigen binding fragment thereof in the treatment of tumors.
• the disclosure also relates to methods for the treatment of a tumor comprising administering to a patient in need thereof an anti-CD73 antibody, such as oleclumab, or antigen-binding fragment thereof in combination with a monoclonal antibody directed against PD-L1, such as durvalumab, or an antigen-binding fragment thereof.
• the disclosure also relates to methods for the treatment of a tumor comprising administering to a patient in need thereof an anti-CD73 antibody, such as oleclumab, or antigen binding fragment thereof in combination with an anti-PD-Ll antibody such as durvalumab, in combination with chemotherapy.
• an anti-CD73 antibody such as oleclumab
• an anti-PD-Ll antibody such as durvalumab
• antibody refers to a protein that is capable of recognizing and specifically binding to an antigen.
• Ordinary or conventional mammalian antibodies comprise a tetramer, which is typically composed of two identical pairs of polypeptide chains, each pair consisting of one "light” chain (typically having a molecular weight of about 25 kDa) and one "heavy” chain (typically having a molecular weight of about 50-70 kDa).
• each light and heavy chain typically includes a variable domain of about 100 to 110 or more amino acids that typically is responsible for antigen recognition.
• the carboxy-terminal portion of each chain typically defines a constant domain responsible for effector function.
• a full-length heavy chain immunoglobulin polypeptide includes a variable domain (VH) and three constant domains (CHI, CH2, and Go) and a hinge region between CHI and Cm, wherein the VH domain is at the amino-terminus of the polypeptide and the Cm domain is at the carboxyl-terminus
• a full-length light chain immunoglobulin polypeptide includes a variable domain (VL) and a constant domain (CL), wherein the VL domain is at the amino-terminus of the polypeptide and the CL domain is at the carboxyl-terminus.
• variable and constant domains typically are joined by a "J" region of about 12 or more amino acids, with the heavy chain also including a "D" region of about 10 more amino acids.
• the variable regions of each light/heavy chain pair typically form an antigen-binding site.
• the variable domains of naturally occurring antibodies typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hypervariable regions, also called complementarity determining regions or CDRs.
• the CDRs from the two chains of each pair typically are aligned by the framework regions, which may enable binding to a specific epitope.
• both light and heavy chain variable domains typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
• antigen-binding fragment refers to a portion of an intact antibody and/or refers to the antigenic determining variable domains of an intact antibody. It is known that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, linear antibodies, single chain antibodies, diabodies, and multispecific antibodies formed from antibody fragments.
• patient as used herein includes human subjects.
• a “disorder” is any condition that would benefit from treatment using the antibodies of the disclosure.
• “Disorder” and “condition” are used interchangeably herein and include chronic and acute disorders or diseases, including those pathological conditions that predispose a patient to the disorder in question.
• solid tumor refers to an abnormal mass of tissue that normally does not contain cysts or liquid areas.
• solid tumors include squamous cell carcinoma of the head and neck, cervical cancer, colorectal cancer, non-small cell lung cancer, pancreatic cancer, prostate cancer, and urothelial bladder cancer.
• treatment or “treat” as used herein refer to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include patients having a tumor as well as those prone to have a tumor or those in which a tumor is to be prevented.
• the antibodies disclosed herein can be used to treat tumors such as solid tumors.
• treatment of a tumor includes inhibiting tumor growth, promoting tumor reduction, or both.
• composition or “therapeutic composition” as used herein refer to a compound or composition capable of inducing a desired therapeutic effect when properly administered to a patient.
• a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one antibody of the disclosure.
• pharmaceutically acceptable carrier or “physiologically acceptable carrier” as used herein refers to one or more formulation materials suitable for accomplishing or enhancing the delivery of one or more antibodies of the disclosure.
• oleclumab and “MEDI9447” as used herein refer to a human
• immunoglobulin G1 lambda (IgGl l) mAh that selectively binds to and inhibits the
• oleclumab or an antigen binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain.
• oleclumab comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 2.
• oleclumab or an antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 3- 5, and wherein the light chain variable domain comprises CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 6-8.
• a tumor in a human patient is treated by administering oleclumab or an antigen-binding fragment thereof to the patient.
• the monotherapy dose of oleclumab or an antigen-binding fragment thereof to be administered to the patient will vary depending, in part, upon the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient.
• the patient is administered one or more doses of oleclumab or an antigen-binding fragment thereof as a monotherapy or in a combination therapy, wherein the dose of oleclumab or an antigen-binding fragment thereof is 750 mg to 3000 mg.
• the dose of the oleclumab or an antigen-binding fragment thereof is 750 mg.
• the dose of the oleclumab or an antigen-binding fragment thereof is 1500 mg.
• the dose of the oleclumab or an antigen-binding fragment thereof is 2250 mg.
• the dose of the oleclumab or an antigen-binding fragment thereof is 3000 mg.
• the patient is administered one or more doses of oleclumab or an antigen-binding fragment thereof as a monotherapy, wherein the dose is, 5 mg/kg, 10 mg/kg, 20 mg/kg, or 40 mg/kg.
• the patient is administered one or more doses of oleclumab or an antigen-binding fragment thereof as a monotherapy wherein the dose is 40 mg/kg.
• a patient presenting with a tumor is administered oleclumab or an antigen-binding fragment thereof only once or infrequently while still providing benefit to the patient.
• the patient is administered additional follow-on doses.
• follow-on doses can be administered at various time intervals depending on the patient's age, weight, clinical assessment, tumor burden, and/or other factors, including the judgment of the attending physician.
• a bolus loading dose of oleclumab or an antigen-binding fragment thereof is administered to a patient presenting with a tumor.
• a patient will be administered a first dose of oleclumab or an antigen-binding fragment thereof followed by a second lower dose of oleclumab or an antigen-binding fragment thereof.
• the second lower dose can be repeated every 14 days to 28 days.
• the first dose of oleclumab is 40 mg/kg and the second lower dose of oleclumab is 20 mg/kg.
• oleclumab or an antigen-binding fragment thereof is administered over a two-week treatment period, over a four- week treatment period, over a six- week treatment period, over an eight-week treatment period, over a twelve-week treatment period, over a twenty-four-week treatment period, or over a one-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof is administered over a three-week treatment period, over a six-week treatment period, over a nine-week treatment period, over a twelve-week treatment period, over a twenty-four-week treatment period, or over a one-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof is administered over a two-month treatment period, over a four-month treatment period, or over a six-month or more treatment period.
• oleclumab or an antigen-binding fragment thereof is administered over a one-year treatment period, over a two-year treatment period, over a three-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof is administered every week, every two weeks, every four weeks, every six weeks, every eight weeks, every 10 weeks, or every twelve weeks.
• the administration of oleclumab or an antigen-binding fragment thereof is repeated every 7 to 28 days. In other embodiments, the administration of oleclumab or an antigen-binding fragment thereof is repeated every 14 days. In further embodiments, the administration of oleclumab or an antigen-binding fragment thereof is repeated every 28 days.
• the administration of oleclumab or an antigen-binding fragment thereof is repeated every 7 to 28 days (e.g., every 7 days, every 14 days, every 21 days or every 28 days).
• oleclumab or an antigen-binding fragment thereof is administered every 14 days for at least two doses (e.g., for two, three, or four doses) and then every 28 days.
• oleclumab or an antigen-binding fragment thereof is administered every 21 days for at least two doses (e.g., for two, three, or four doses) and then every 28 days.
• 750-3000 mg e.g., 750, 1500, 2250, or 3000 mg
• oleclumab or an antigen-binding fragment thereof can be administered in a combination therapy with durvalumab or an antigen-binding fragment thereof.
• durvalumab refers to an antibody that selectively binds PD- L1 and blocks the binding of PD-L1 to the PD-1 and CD80 receptors, as disclosed in U.S. Patent No. 9,493,565, which is incorporated by reference herein in its entirety.
• the fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgGl heavy chain that reduces binding to the complement component Clq and the Fey receptors responsible for mediating antibody-dependent cell-mediated cytotoxicity (ADCC).
• durvalumab or an antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain.
• durvalumab comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 9 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 10.
• durvalumab or an antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 11-13, and wherein the light chain variable domain comprises CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 14-16.
• a patient presenting with a tumor is administered oleclumab or an antigen-binding fragment thereof in combination with durvalumab or an antigen-binding fragment thereof only once or infrequently while still providing benefit to the patient.
• the patient is administered additional follow-on doses.
• follow- on doses can be administered at various time intervals depending on the patient's age, weight, clinical assessment, tumor burden, and/or other factors, including the judgment of the attending physician.
• oleclumab or an antigen-binding fragment thereof administered in a combination therapy with durvalumab or an antigen-binding fragment thereof is administered over a two-week treatment period, over a four-week treatment period, over a six- week treatment period, over an eight-week treatment period, over a twelve-week treatment period, over a twenty-four-week treatment period, or over a one-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof is administered over a three-week treatment period, over a six-week treatment period, over a nine-week treatment period, over a twelve-week treatment period, over a twenty-four-week treatment period, or over a one-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof administered is administered over a two-month treatment period, over a four-month treatment period, or over a six-month or more treatment period.
• oleclumab or an antigen-binding fragment thereof administered in a combination therapy with durvalumab or an antigen-binding fragment thereof is administered every two weeks, every three weeks, every four weeks, every six weeks, every eight weeks, every 10 weeks, or every twelve weeks.
• oleclumab or an antigen-binding fragment thereof in a combination therapy with durvalumab or an antigen binding fragment thereof is administered over a one-year treatment period, over a two-year treatment period, over a three-year or more treatment period.
• the administration of oleclumab or an antigen-binding fragment thereof in a combination therapy with durvalumab or an antigen-binding fragment thereof is repeated every 14 to 28 days. In other embodiments, the administration of oleclumab or an antigen-binding fragment thereof is repeated every 14 days. In other embodiments, the administration of oleclumab or an antigen-binding fragment thereof is repeated every 21 days.
• the administration of oleclumab or an antigen-binding fragment thereof is repeated every 28 days.
• the administration of oleclumab or an antigen-binding fragment thereof is every 14 days for at least two doses (e.g., for two , three, or four doses) and then every 28 days.
• the administration of oleclumab or an antigen-binding fragment thereof is every 21 days for at least two doses (e.g., for two, three, or four doses) and then every 28 days.
• durvalumab is administered about as frequently as oleclumab.
• the administration of durvalumab is repeated every 14 to 28 days.
• the administration of durvalumab is repeated every 14 days.
• the administration of durvalumab is repeated every 21 days.
• the administration of durvalumab is repeated every 28 days.
• the administration of durvalumab is repeated every 21 days for at least two doses (e.g., for two doses, three doses, or four doses), and then repeated every 28 days.
• the combination therapy dose of oleclumab or an antigen-binding fragment thereof with durvalumab will vary depending, in part, upon the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient.
• the patient is administered one or more doses of oleclumab or an antigen-binding fragment thereof as a combination therapy wherein the dose is 5 mg/kg, 10 mg/kg, 20 mg/kg, or 40 mg/kg.
• the patient is administered one or more doses of oleclumab or an antigen-binding fragment thereof as a combination therapy wherein the dose of oleclumab or antigen-binding fragment thereof is 750 mg, 1500 mg, 2250 mg, or 3000 mg.
• the combination therapy dose of durvalumab with oleclumab will vary depending, in part, upon the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient.
• the patient is administered one or more doses of durvalumab or an antigen-binding fragment thereof as a combination therapy wherein the dose is 3 mg/kg, 10 mg/kg or 20 mg/kg.
• the patient is administered one or more doses of durvalumab or an antigen-binding fragment thereof as a combination therapy wherein the dose of durvalumab or antigen-binding fragment thereof is 1500 mg.
• a bolus loading dose of oleclumab or an antigen-binding fragment and/or durvalumab or an antigen-binding fragment thereof is administered to a patient presenting with a tumor.
• a patient will be administered a first dose of oleclumab or an antigen-binding fragment and/or durvalumab or an antigen-binding fragment followed by a second lower dose of oleclumab or an antigen-binding fragment and/or durvalumab or an antigen-binding fragment thereof.
• the patient is administered 2 mg/kg oleclumab or an antigen-binding fragment thereof every two weeks and 10 mg/kg of durvalumab or an antigen binding fragment thereof every 2 weeks.
• the patient is administered 5 mg/kg oleclumab or an antigen-binding fragment thereof every two weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 10 mg/kg oleclumab or an antigen-binding fragment thereof every two weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 20 mg/kg oleclumab or an antigen-binding fragment thereof every two weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 40 mg/kg oleclumab or an antigen-binding fragment thereof every two weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 2 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 10 mg/kg of durvalumab or an antigen binding fragment thereof every 2 weeks.
• the patient is administered 5 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 10 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 20 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 40 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 10 mg/kg of durvalumab or an antigen-binding fragment thereof every 2 weeks.
• the patient is administered 2 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen binding fragment thereof every four weeks.
• the patient is administered 2 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen binding fragment thereof every four weeks.
• the patient is administered 2 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen binding fragment thereof every four weeks.
• the patient is administered 2 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen binding fragment thereof every four weeks.
• the patient is administered 2 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen binding fragment thereof every four weeks.
• the patient is administered 5 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen-binding fragment thereof every four weeks.
• the patient is administered 10 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen-binding fragment thereof every four weeks.
• the patient is administered 20 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen-binding fragment thereof every four weeks.
• the patient is administered 40 mg/kg oleclumab or an antigen-binding fragment thereof every four weeks and 20 mg/kg of durvalumab or an antigen-binding fragment thereof every four weeks.
• the patient is administered 1500 mg or 3000 mg of oleclumab or antigen binding fragment thereof every 2 weeks for two 28-day cycles doses and then every 4 weeks and 1500 mg durvalumab or an antigen-binding fragment thereof every 4 weeks.
• the patient is administered 3000 mg of oleclumab or antigen binding fragment thereof every 2 weeks and 1500 mg durvalumab or an antigen-binding fragment thereof.
• the patient is administered 3000 mg of oleclumab or antigen binding fragment thereof every 2 weeks for two months and then every 4 weeks and 1500 mg durvalumab or an antigen-binding fragment thereof every 4 weeks.
• oleclumab or an antigen-binding fragment thereof can be administered in a combination therapy with chemotherapy.
• a patient presenting with a tumor is administered oleclumab or an antigen-binding fragment thereof in combination with chemotherapy only once or infrequently while still providing benefit to the patient.
• the patient is administered additional follow-on doses.
• follow-on doses can be administered at various time intervals depending on the patient's age, weight, clinical assessment, tumor burden, and/or other factors, including the judgment of the attending physician.
• oleclumab or an antigen-binding fragment thereof in combination with chemotherapy is administered over a two-week treatment period, over a three- week period, over a four- week treatment period, over a six-week treatment period, over an eight- week treatment period, over a twelve-week treatment period, over a twenty-four-week treatment period, or over a one-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof is administered over a three- week treatment period, over a six- week treatment period, over a nine-week treatment period, over a twelve- week treatment period, over a twenty-four- week treatment period, or over a one-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof is administered over a two-month treatment period, over a four-month treatment period, or over a six-month or more treatment period.
• oleclumab or an antigen-binding fragment thereof in a combination therapy with chemotherapy is administered over a one-year treatment period, over a two-year treatment period, over a three-year or more treatment period.
• oleclumab or an antigen-binding fragment thereof in combination with chemotherapy is administered every two weeks, every three weeks every four weeks, every six weeks, every eight weeks, every 10 weeks, or every twelve weeks. [00130] In particular embodiments, the administration of oleclumab or an antigen-binding fragment thereof in combination with chemotherapy is repeated every 14 to 28 days. In other embodiments, the administration of oleclumab or an antigen-binding fragment thereof in is repeated every 14 days. In other embodiments, the administration of oleclumab or an antigen binding fragment thereof in is repeated every 21 days. In further embodiments, the
• administration of oleclumab or an antigen-binding fragment thereof in is repeated every 28 days.
• the administration of oleclumab or an antigen-binding fragment thereof is every 14 days for at least two doses (e.g., for two , three, or four doses) and then every 28 days
• the administration of oleclumab or an antigen-binding fragment thereof is every 21 days for at least two doses (e.g., for two, three, or four doses) and then every 28 days.
• the combination therapy dose of oleclumab or an antigen-binding fragment thereof with chemotherapy will vary depending, in part, upon the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient.
• the patient is administered one or more doses of oleclumab or an antigen-binding fragment thereof in combination with chemotherapy wherein the dose of oleclumab or an antigen-binding fragment thereof in is 750 mg, 1500 mg or 3000 mg.
• the patient is administered one or more doses of oleclumab or an antigen-binding fragment thereof in combination with chemotherapy wherein the dose of oleclumab or an antigen-binding fragment thereof in is 2250 mg.
• the chemotherapy comprises at least one of cisplatin, pemetrexed. nab-paclitaxel, carboplatin, gemcitabine, cisplatin, oxaliplatin, leucovorin, 5- fluorouracil, and docetaxel.
• the chemotherapy comprises a combination of at least two of cisplatin, pemetrexed. nab-paclitaxel, carboplatin, gemcitabine, cisplatin, oxaliplatin, leucovorin, 5-fluorouracil, and docetaxel.
• the chemotherapy comprises oxaliplatin, leucovorin, and 5-fluorouracil.
• the chemotherapy comprises nab-paclitaxel and carboplatin.
• the chemotherapy comprises gemcitabine and cisplatin.
• the chemotherapy comprises gemcitabine and carboplatin.
• the chemotherapy comprises pemetrexed and carboplatin.
• the chemotherapy comprises pemetrexed and cisplatin.
• the chemotherapy comprises at least one of gemcitabine, nab-paclitaxel, oxaliplatin, leucovorin and 5-fluorouracil.
• the combination therapy dose of chemotherapy with oleclumab will vary depending, in part, upon the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient.
• Oleclumab can be used in combination with chemotherapy utilizing any chemotherapy regimen known in the art.
• the patient is administered one or more doses of gemcitabine at a dose of 1000 mg/m 2 and nab-paclitaxel at a dose of 125 mg/m 2 .
• the patient is administered one or more doses of oxaliplatin at a dose of 85 mg/m 2 , leucovorin at a dose of 400 mg/m 2 and 5-fluorouracil at a dose of 2400 mg/m 2 .
• the patient is administered one or more doses of 85 mg/m 2 oxaliplatin.
• the patient is administered one or more doses of 400 mg/m 2 leucovorin.
• the patient is administered one or more doses of 2400 mg/m 2 5-fluorouracil (5-FU).
• the patient is administered one or more doses of 85 mg/m 2 oxaliplatin, 400 mg/m 2 leucovorin and 2400 mg/m 2 5-fluorouracil.
• the patient is administered one or more doses of 100 mg/m 2 nab-paclitaxel. In particular embodiments, the patient is administered one or more doses of 1000 or 1250 mg/m 2 gemcitabine. In particular embodiments, the patient is administered one or more doses of 500 mg/m 2 pemetrexed. In particular embodiments, the patient is administered one or more doses of AUC 5 or 6 carboplatin. In particular embodiments, the patient is administered one or more doses of 75 mg/m 2 cisplatin.
• chemotherapy is administered about as frequently as oleclumab.
• the administration of chemotherapy is repeated every 7 to 28 days.
• the administration of chemotherapy is repeated every 7 days.
• the administration of chemotherapy is repeated every 14 days.
• the administration of chemotherapy is repeated every 21 days.
• the administration of chemotherapy is repeated every 28 days.
• the administration of chemotherapy is repeated on days 1 and 8 of a 21 -day cycle
• oleclumab or an antigen-binding fragment thereof can be administered in a combination therapy with chemotherapy and durvalumab or an antigen-binding fragment thereof.
• the combination therapy including oleclumab, durvalumab and chemotherapy, durvalumab is administered about as frequently as oleclumab.
• oleclumab is administered about twice as frequently as durvalumab.
• the administration of durvalumab is repeated every 14 to 28 days. In other embodiments the administration of durvalumab is repeated every 14 days.
• the administration of durvalumab is repeated every 21 days. In further embodiments, the administration of durvalumab is repeated every 28 days. In further embodiments, the administration of durvalumab is repeated every 21 days for at least two doses
• the combination therapy dose of durvalumab or an antigen-binding fragment thereof with oleclumab or an antigen-binding fragment thereof and chemotherapy will vary depending, in part, upon the size (body weight, body surface, or organ size) and condition (the age and general health) of the patient.
• the patient is administered one or more doses of durvalumab or an antigen-binding fragment thereof as a combination therapy wherein the dose or durvalumab or an antigen-binding fragment thereof is 1500 mg.
• the patient is administered 750 mg of oleclumab or an antigen-binding fragment thereof every 2 weeks for four doses and then every 4 weeks, 1500 mg of durvalumab or an antigen-binding fragment thereof every 4 weeks, and 1000 mg/m 2 gemcitabine and 125 mg/m 2 nab-paclitaxel on days 1, 8 and 15 then every 4 weeks.
• the patient is administered 1500 mg of oleclumab or an antigen-binding fragment thereof every 2 weeks for four doses and then every 4 weeks, 1500 mg of durvalumab or an antigen-binding fragment thereof every 4 weeks, and 1000 mg/m 2 gemcitabine and 125 mg/m 2 nab-paclitaxel on days 1, 8 and 15 then every 4 weeks.
• the patient is administered 3000 mg of oleclumab or an antigen-binding fragment thereof every 2 weeks for four doses and then every 4 weeks, 1500 mg of durvalumab or an antigen-binding fragment thereof every 4 weeks, and 1000 mg/m 2 gemcitabine and 125 mg/m 2 nab-paclitaxel on days 1, 8 and 15 then every 4 weeks.
• the patient is administered 750 mg of oleclumab or an antigen-binding fragment thereof every 2 weeks for four doses and then every 4 weeks, 1500 mg of durvalumab or an antigen-binding fragment thereof every 4 weeks, and 85 mg/m 2 oxaliplatin, 400 mg/m 2 leucovorin and 2400 mg/m 2 5-fluorouracil on days 1 and 15 and then every 4 weeks.
• the patient is administered 1500 mg of oleclumab or an antigen binding fragment thereof every 2 weeks for four doses and then every 4 weeks, 1500 mg of durvalumab or an antigen-binding fragment thereof every 4 weeks, and 85 mg/m 2 oxaliplatin,
• the patient is administered 3000 mg of oleclumab or an antigen binding fragment thereof every 2 weeks for four doses and then every 4 weeks, 1500 mg of durvalumab or an antigen-binding fragment thereof every 4 weeks, and 85 mg/m 2 oxaliplatin,
• the patient is administered 1500 mg or 3000 mg of oleclumab or antigen binding fragment thereof every 2 weeks for four doses and then every 4 weeks and chemotherapy comprising 1000 mg/m 2 gemcitabine and 125 mg/m 2 nab-paclitaxel.
• the chemotherapy can be administered on days 1, 8, and 15 of four 28-day cycles and then every 4 weeks.
• 1500 mg durvalumab or an antigen-binding fragment thereof can be administered every 4 weeks.
• the patient is administered 1500 mg or 3000 mg of oleclumab or antigen binding fragment thereof every 2 weeks for four doses and then every 4 weeks and chemotherapy comprising 85 mg/m 2 oxaliplatin, 400 mg/m 2 leucovorin, and 400 mg/m 2 5-FU followed by 2400 mg/m 2 5-FU.
• the chemotherapy can be administered on days 1 and 15 of four 28-day cycles and then every 4 weeks.
• 1500 mg durvalumab or an antigen-binding fragment thereof can be administered every 4 weeks.
• the patient is administered (i) oleclumab or antigen binding fragment thereof is administered (a) at 1500 mg every 3 weeks for four 21 -day cycles and then every 4 weeks; or (b) at 2250 mg every 3 weeks for four 21 -day cycles and then at 3000 mg every 4 weeks; (ii) durvalumab or antigen binding fragment thereof at 1500 mg every 3 weeks for four 21 -day cycles and then every 4 weeks; and (iii) chemotherapy comprising: (a)
• the patient is administered (i) 1500 mg durvalumab or an antigen-binding fragment thereof every 4 weeks; (ii) 3000 mg oleclumab or an antigen-binding fragment thereof every 2 weeks for five doses and then every 4 weeks; and (iii) chemotherapy comprising (a) 400 mg/m 2 of folinic acid every 2 weeks (b) 85 mg/m 2 oxaliplatin every 2 weeks; and (c) 400 mg/m 2 of 5-fluorouracil on day 1 and then 2400 mg/m2 of 5-fluorouracil every 2 weeks.
• bevacizumab or an antigen-binding fragment thereof can be administered in a combination therapy with oleclumab or an antigen-binding fragment thereof and chemotherapy (e.g., with chemotherapy comprising oxaliplatin, leucovorin and 5- fluorouracil).
• chemotherapy e.g., with chemotherapy comprising oxaliplatin, leucovorin and 5- fluorouracil.
• bevacizumab refers to an antibody that selectively binds vascular endothelial growth factor (VEGF), as disclosed in US Patents Nos. 6,884,879 and 7,169,901, which are incorporated by reference herein in its entirety.
• VEGF vascular endothelial growth factor
• bevacizumab or an antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain.
• bevacizumab comprises a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 17 and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 18.
• durvalumab or an antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 19-21, and wherein the light chain variable domain comprises CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 22-24.
• the patient is administered one or more doses of 5 mg/kg bevacizumab or an antigen-binding fragment thereof.
• the bevacizumab or an antigen-binding fragment thereof can be administered, e.g., every 2 weeks.
• the bevacizumab or an antigen binding fragment thereof can be administered, e.g., intravenously.
• the patient is administered (i) 1500 mg durvalumab or an antigen-binding fragment thereof every 4 weeks; (ii) 3000 mg oleclumab or an antigen-binding fragment thereof every 2 weeks for four doses and then every 4 weeks; (iii) chemotherapy comprising (a) 400 mg/m 2 of folinic acid every 2 weeks (b) 85 mg/m 2 oxaliplatin every 2 weeks; and (c) 2400 mg/m 2 of 5-fluorouracil every 2 weeks; and (iv) 5 mg/kg of bevacizumab or an antigen-binding fragment thereof is administered every 2 weeks.
• the patient receiving treatment has a solid tumor that is a is a breast cancer, ovarian cancer, head and neck cancer, prostate cancer, bladder cancer, colorectal cancer, non-small cell lung cancer (NSCLC), glioblastoma, renal cell cancer, or pancreatic cancer.
• a solid tumor that is a is a breast cancer, ovarian cancer, head and neck cancer, prostate cancer, bladder cancer, colorectal cancer, non-small cell lung cancer (NSCLC), glioblastoma, renal cell cancer, or pancreatic cancer.
• NSCLC non-small cell lung cancer
• the patient receiving treatment has a solid tumor such as colorectal cancer, non-small cell lung cancer, or pancreatic cancer.
• the patient has pancreatic ductal adenocarcinoma.
• the patient has metastatic pancreatic ductal adenocarcinoma that has not been previously treated.
• the patient has metastatic pancreatic ductal adenocarcinoma that was previously treated with gemcitabine-based therapy.
• the patient has a resectable NSCLC tumor, an early-stage NSCLC tumor, or stage IV NSCLC tumor.
• the patent has metastatic colorectal cancer.
• the patient has a tumor with high-PD-Ll expression or with low-PD-Ll expression.
• the tumor with high-PD-Ll expression or low-PD-Ll expression can be a NSCLC.
• the patient has a tumor that lacks an activating epidermal growth factor receptor (EGFR) mutation and /or an anaplastic lymphoma kinase (ALK) fusion.
• the tumor can be a NSCLC tumor.
• the patient has a tumor has not received prior treatment in the recurrent and/or metastatic setting.
• the antibodies of the disclosure can be selected for parenteral administration.
• the antibodies of the disclosure can be administered by intravenous infusion or by subcutaneous injection.
• the administration is by intravenous infusion.
• RECIST Solid Tumors
• CR complete response
• PR partial response
• PD progressive disease
• SD stable disease
• the methods provided herein can be used for disease control (DC) of a tumor.
• Disease control can be a complete response (CR), partial response (PR), or stable disease (SD).
• CR complete response
• PR partial response
• SD stable disease
• a "complete response” refers to the disappearance of all lesions, whether measurable or not, and no new lesions. Confirmation of a complete response can be obtained using a repeat, consecutive assessment no less than four weeks from the date of first
• a "partial response" refers to a decrease in tumor burden of > 50% relative to baseline. Confirmation can be obtained using a consecutive repeat assessment at least 4 weeks from the date of first documentation.
• PD Progressive disease
• SD stable disease
• a method of treating a tumor in a human patient comprises administering oleclumab or antigen-binding fragment thereof to the patient.
• the oleclumab or antigen-binding fragment thereof is administered at a dose of 2 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, or 40 mg/kg.
• the oleclumab or antigen-binding fragment thereof is administered at a dose of 40 mg/kg.
• the oleclumab or antigen-binding fragment thereof is administered every 14 to 28 days.
• the oleclumab or antigen-binding fragment thereof is administered every 14 days.
• the oleclumab or antigen-binding fragment thereof is administered every 28 days. [00173] In one aspect of any one of A1-A6 (A7), the administration of oleclumab or antigen binding fragment thereof results in a partial response.
• the tumor is a solid tumor.
• the solid tumor is colorectal cancer, non-small cell lung cancer, or pancreatic cancer.
• the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• ECG Eastern Cooperative Oncology Group
• a method of treating a solid tumor in a human patient comprises administering 40 mg/kg of oleclumab or antigen-binding fragment thereof to the patient.
• a method of treating a tumor in a human patient comprises administering oleclumab or antigen-binding fragment thereof and durvalumab or antigen-binding fragment thereof to the patient.
• the oleclumab or antigen-binding fragment thereof is administered at a dose of 2 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, or 40 mg/kg.
• the durvalumab or antigen-binding fragment thereof is administered at a dose of 3 mg/kg, 10 mg/kg or 20 mg/kg.
• the oleclumab or antigen-binding fragment thereof is administered every 14 days to 28 days.
• the durvalumab or antigen-binding fragment thereof is administered every 14 days to 28 days.
• the tumor is a solid tumor.
• the solid tumor is colorectal cancer, non-small cell lung cancer, or pancreatic cancer.
• the patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• ECG Eastern Cooperative Oncology Group
• a method of treating a tumor in a human patient comprises administering oleclumab or antigen-binding fragment thereof and chemotherapy to the patient.
• the oleclumab or antigen-binding fragment thereof is administered at a dose of 750 mg, 1500 mg or 3000 mg.
• the oleclumab or antigen-binding fragment thereof is administered every 14 days to 28 days.
• the method further comprises administering durvalumab or antigen-binding fragment thereof.
• the durvalumab or antigen-binding fragment thereof is administered at a dose of 1500 mg.
• the durvalumab or antigen-binding fragment thereof is administered every 28 days.
• the chemotherapy comprises at least one of gemcitabine, nab-paclitaxel, oxaliplatin, leucovorin and 5-fluorouracil.
• the chemotherapy comprises 1000 mg/m 2 gemcitabine and 125 mg/m 2 nab-paclitaxel.
• the chemotherapy comprises 85 mg/m 2 oxaliplatin, 400 mg/m 2 leucovorin and 2400 mg/m 2 5-fluorouracil.
• the chemotherapy is administered every 7 days to 28 days.
• 5-fluorouracil is administered by continuous intravenous infusion for 46 to 48 hours.
• the patient has metastatic pancreatic ductal
• the patient has metastatic pancreatic ductal
• Example 1 Evaluation of Toxicity of Oleclumab in Mouse and Monkey Species
• Mouse and cynomolgus monkey were selected as pharmacologically relevant species for evaluation of the toxicity of oleclumab. This assessment was based on a composite of factors: (i) moderate-to-high protein sequence identity between mouse and cynomolgus monkey CD73 and human CD73 (86% and 98%, respectively); (ii) similar binding affinity of oleclumab for mouse, cynomolgus monkey, and human CD73; and (iii) similar potency of oleclumab against mouse, monkey, and human recombinant CD73 enzyme activity in cell-based in vitro assays. Additionally, in cynomolgus monkeys, single IV doses of > 1 mg/kg oleclumab (lowest dose tested) suppressed soluble CD73 in the serum, with a dose-related duration of suppression.
• GLP Good Laboratory Practice
• CD-I mice 5 -week, repeat intravenous [IV] bolus dose, once every 4 days, total 9 doses
• cynomolgus monkeys 5-week, repeat IV 30-minute infusion dose, once weekly, total 5 doses
• No oleclumab-related adverse effects were noted in CD-I mice at doses up to 200 mg/kg or in cynomolgus monkeys at doses up to 300.7 mg/kg.
• the no-observed-adverse-effect level was considered to be 200 mg/kg/dose (the highest dose tested; maximum observed concentration [Cmax], 6,200 pg/mL; area under the concentration-time curve [AUC]o-96hr, 229,000 pg hr/mL) in CD-I mice and 300.7 mg/kg/dose (the highest dose tested; Cmax, 11,000 pg/mL; AUCo-i68.5hr, 834,000 pg hr/mL) in cynomolgus monkeys.
• the GLP human tissue cross reactivity evaluation staining with oleclumab was observed in multiple cell types throughout the human tissue panel examined.
• oleclumab (alone or in combination with durvalumab) to induce cytokine release was evaluated in human in vitro assays using blood or peripheral blood mononuclear cell from healthy donors. Oleclumab alone or in combination with durvalumab, presented in solution or immobilized on plastic wells by dry-coating, did not induce cytokine release.
• KLH exogenous antigen
• the exogenous antigen (KLH) response was determined by first immunizing the monkeys on day 1 with adjuvant free KLH.
• KLH T cell-dependent antibody response (TDAR) was conducted on days 7, 8, 11, 15, 22, 29, and 36.
• Ex vivo KLH stimulation of PBMC IFN-g and IL-2 ELISPOT was determined on days 1, 4, 8, 7, 15, and 22.
• Oleclumab did not enhance responses to exogenous antigen (KLH).
• Anti-KLH IgM and IgG antibody responses were detectable but did not show dose-dependent increase with oleclumab treatment ( Figures 2A and 2B).
• T cell responses to ex vivo KLH stimulation were detectable but did not vary with oleclumab treatment ( Figures 3A and 3B).
• Endogenous pathogen response was also investigated by endogenous pathogen verification. Endogenous pathogen antibodies were measured using chemiluminescent ELISA on days 1, 8, 14, 15, and 29 and endogenous pathogen T cell IFN-g ELISPOT was measured on days -14 and 29. LCV (monkey homologue of EBV) was detectable at low levels in most cynomolgus monkeys ( Figure 4). IgG titers to EBV gpl25 and CMV gB were detectable but did not vary with oleclumab treatment. T cell responses to EBV BZLF1 and inactivated human CMV were detectable but did not vary consistently with oleclumab treatment
• Example 3 Oleclumab Monotherapy and in Combination with Durvalumab in Solid Tumor Treatment
• the study was a first-time- in- human (FTIH), Phase 1, multicenter, open- label, dose- escalation, and dose-expansion study of oleclumab administered as a single agent or in combination with durvalumab in adult subjects to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity in adult subjects with selected advanced solid tumors.
• FTIH first-time- in- human
• Phase 1 Phase 1
• Phase 1 Phase 1
• PK pharmacodynamics
• preliminary antitumor activity in adult subjects with selected advanced solid tumors.
• the study flow diagrams for dose escalation and dose expansion for this part of the study are illustrated in Figures 7A and 7B.
• DLT dose-limiting toxicity
• MSS-CRC microsatellite stable CRC.
• the endpoints for assessment of antitumor activity included objective response (OR), disease control (DC), duration of response (DoR), progression-free survival (PFS), and overall survival (OS).
• RECIST vl .1 was used for assessment of tumor response.
• Pharmacokinetic parameters included, but were not limited to, maximum observed
• the endpoints for assessment of immunogenicity of oleclumab and durvalumab included the number and percentage of subjects who developed detectable anti-drug antibodies and the endpoints for assessment of pharmacodynamic activity included assessment of target expression (e.g., CD73, PD-L1) in tumor biopsy specimens.
• target expression e.g., CD73, PD-L1
• the subject population included subjects > 18 years of age, with histologically- or cytologically-confirmed colorectal adenocarcinoma (CRC) or pancreatic adenocarcinoma. Subjects with CRC or pancreatic adenocarcinoma must have received and progressed, were refractory, or were intolerant to standard therapy.
• CRC colorectal adenocarcinoma
• pancreatic adenocarcinoma pancreatic adenocarcinoma.
• subjects with CRC or pancreatic adenocarcinoma had not received more than five prior lines of therapy.
• Subjects with CRC enrolled in the dose- expansion phase had received at least two including regimens containing a fluoropyrimidine [e.g., 5-FU or capecitabine], oxaliplatin, and irinotecan unless contraindicated) but not more than four prior lines of systemic therapy in the metastatic setting and must not have defective DNA mismatch repair.
• Subjects with KRAS mutation for example, exon 2, codon 12 or 13 were allowed.
• pancreatic adenocarcinoma enrolled in the dose-expansion phase must have received one but not more than two prior lines of systemic therapy in the metastatic setting.
• the first twenty subjects with CRC and pancreatic adenocarcinoma in the expansion phase must have had positive CD73 expression by IHC on at least 10% of tumor cells with weak, moderate, or strong staining; or a combination of such staining.
• All subjects were required to have at least 1 lesion that was measurable using RECIST guidelines, an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1, as well as adequate organ function.
• ECOG Eastern Cooperative Oncology Group
• Adequate organ function was defined as: absolute neutrophil count > 1,500/mm 3 ; platelet count > 75,000/ mm 3 ; Prothrombin time-international normalized ratio and partial thromboplastin time ⁇ 1.5 x ULN; hemoglobin > 9.0 g/dL; creatinine clearance or 24- hour urine CrCl > 50 mL/min as determined by the Cockcroft-Gault formula; total bilirubin ⁇
• Subjects were excluded from participation in the study if administered prior treatment with a TNFRSL agonist, received prior therapy with regimens containing CTLA-4, PD-L1, or PD-1 antagonists for subjects with CRC or pancreatic adenocarcinoma, required the use of additional immunosuppression other than corticosteroids for the management of an AE, experienced recurrence of an AE if re-challenged, and currently required maintenance doses of > 10 mg prednisone or equivalent per day, received any conventional or investigational anticancer therapy within 28 days prior to the first dose of oleclumab within 14 days of the first dose of oleclumab, or received any concurrent chemotherapy, immunotherapy or biologic or hormonal therapy for cancer treatment.
• the dose-escalation phase of the study consisted of 2 arms: (i) ascending dose levels of oleclumab monotherapy and (ii) ascending dose levels of oleclumab in combination with a single dose level of durvalumab, both administered in subjects with advanced CRC or pancreatic adenocarcinoma.
• oleclumab monotherapy dose-escalation arm sequential cohorts of 3 to 6 subjects each received 1 of 4 dose levels of oleclumab (5, 10, 20, or 40 mg/kg) via IV infusion Q2W unless the maximum tolerated dose (MTD) was reached before all dose-escalation cohorts were completed (Ligure 8).
• MTD maximum tolerated dose
• oleclumab/durvalumab combination therapy dose-escalation arm sequential cohorts of 3 to 6 subjects each received 1 of 4 dose levels of oleclumab (5, 10,
• Oleclumab dose selection was based on nonclinical data and clinical safety margins based on nonclinical safety data as described above for mice and monkeys. The
• cynomolgus monkey toxicity study provided safety margins of 19-fold (human equivalent dose [HED]-based), 73-fold (Cmax-based) and 70-fold (AUC-based).
• HED human equivalent dose
• Cmax-based 73-fold
• AUC-based 70-fold
• the dose-escalation scheme in this study was designed to achieve higher and more sustained suppression of CD73 target, while maintaining adequate safety margins.
• the cynomolgus monkey toxicity study provided safety margins of 2-fold (HED- based), 8-fold (Cmax-based), and 8-fold (AUC-based).
• the dose level and treatment schedule for durvalumab (10 mg/kg Q2W) was based on a safe dose established in a Phase 1/2 study to evaluate the safety, tolerability, and PK of durvalumab in subjects with advanced solid tumors.
• the proposed initial oleclumab and durvalumab combination dose level 1 utilized a dose level of durvalumab shown to have an acceptable safety profile (10 mg/kg IV Q2W) with a dose level of oleclumab (5 mg/kg IV Q2W) that was not anticipated to provide maximal inhibition of CD73 throughout the interval of dosing. If the MTD was exceeded prior to the proposed maximal combination doses of 40 mg/kg oleclumab and 10 mg/kg durvalumab, then 3 mg/kg durvalumab was utilized to further explore combination dosing.
• the dose-escalation phase was executed on a 3 + 3 design.
• a minimum of three subjects were enrolled in each dose-level cohort, with administration of the first dose of investigational product staggered by a minimum of 24 hours between the first and second subjects treated in each dose-level cohort. If no dose limiting toxi cities (DLTs) were observed in the first 3 subjects during the DLT-evaluation period) and all available safety data were reviewed by a study-specific dose escalation committee, dose-escalation continued to the next higher dose cohort. If 1 of 3 subjects in a dose-level cohort experienced a DLT, that dose level cohort was expanded to a total of 6 subjects. If no more than 1 of 6 subjects in the dose-level cohort experienced a DLT, dose-escalation continued to the next higher dose-level cohort. Six subjects were enrolled in the highest dose-level cohort that did not exceed the MTD.
• the DCRs in the MSS-CRC and pancreatic adenocarcinoma cohorts were 14.3% (95% Cl: 3.0%, 36.3%) and 20.0% (95% Cl: 5.7%, 43.7%), respectively.
• Oleclumab appeared to exhibit a nonlinear PK at the lowest dose of oleclumab 5 mg/kg and exhibited linear PK at doses of oleclumab 10 mg/kg and higher in both monotherapy and combination therapy cohorts. Serum exposures were similar when oleclumab was administered either alone or in combination with durvalumab.
• the PK exposures (trough plasma concentration [Ctrough]) increased in a more than proportional manner from oleclumab 5 to 10 mg/kg and in an approximately dose proportional manner from oleclumab 10 to 40 mg/kg. Accumulation of oleclumab was observed following repeated dosing; the mean accumulation ratio ranged from 1.15 to 1.46 for Cmax and from 1.68 to 10.7 for Ctrough.
• Oleclumab decreased CD73 surface expression as measured by mean fluorescence intensity (MFI) ( Figure 10A) and percent CD73+ CD4 and CD8 cells (Figure 10B) in peripheral T cells across all doses without a concomitant decrease in total CD4 and CD8 cells ( Figure IOC).
• MFI mean fluorescence intensity
• Figure 10A percent CD73+ CD4 and CD8 cells
• Figure 10B percent CD73+ CD4 and CD8 cells
• a dose-expansion study of oleclumab administered in combination with durvalumab was conducted in adult subjects to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity in adult subjects with selected advanced solid tumors.
• Subjects with NSCLC enrolled in dose-expansion phase must have had EGFR mutation known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) and must have received at least one but not more than 4 prior lines of therapy (including investigational therapy) in the metastatic setting, must have received an approved EGFR TKI and then clinically or radiologically progressed or were intolerant.
• EGFR mutation known to be associated with EGFR TKI sensitivity including G719X, exon 19 deletion, L858R, L861Q
• Subjects were excluded from participation in the study if administered prior treatment with a TNFRSF agonist, had prior exposure to any investigational immunotherapy or receipt of an EGFR TKI, received prior therapy with regimens containing CTLA-4, PD-L1, required the use of additional immunosuppression other than corticosteroids for the management of an AE, experienced recurrence of an AE if re-challenged, and currently required maintenance doses of > 10 mg prednisone or equivalent per day, received any conventional or investigational anticancer therapy within 28 days prior to the first dose of oleclumab within 14 days of the first dose of oleclumab, or received any concurrent chemotherapy, immunotherapy or biologic or hormonal therapy for cancer treatment.
• Dose-expansion of oleclumab/durvalumab combination therapy was initiated once the MTD or MAD was established in the combination therapy arm of the dose-escalation phase.
• the combination therapy dose-expansion phase included the following three tumor-specific cohorts: a) up to 100 subjects with previously treated MSS-CRC, b) up to 100 subjects with previously treated pancreatic adenocarcinoma, and c) up to 40 subjects with previously treated EGFRm NSCLC.
• the overall disease control rate (DCR; 8 weeks) in the dose-expansion phase was 16.7% (95% Cl; 7.0%, 31.4%).
• the DCRs in the MSS-CRC and pancreatic adenocarcinoma cohorts were 14.3% (95% Cl: 3.0%, 36.3%) and 20.0% (95% Cl: 5.7%, 43.7%), respectively.
• Example 5 Oleclumab Treatment with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
• the study is a Phase lb/2, multicenter, open-label, dose-escalation and dose- expansion study to assess the safety, preliminary antitumor activity, immunogenicity, and PK of oleclumab with or without durvalumab in combination with chemotherapy administered in subjects with metastatic pancreatic ductal adenocarcinoma (PD AC).
• Subjects with previously untreated metastatic PD AC (1L metastatic PD AC) were enrolled in Cohort A.
• Subjects with metastatic PD AC previously treated with gemcitabine-based chemotherapy without exposure to 5-FU, capecitabine, or oxaliplatin; 2L metastatic PD AC
• the study consists of 2 parts, dose escalation (Part 1) and dose expansion (Part 2).
• the endpoints for assessment of antitumor activity included objective response (OR), disease control (DC), duration of response (DoR), progression-free survival (PFS), and overall survival (OS).
• RECIST vl .1 was used for assessment of tumor response.
• Pharmacokinetic parameters included, but were not limited to, maximum observed concentration (Cmax), time to reach Cmax (tmax), AUC, clearance, apparent volume of distribution (Vd), and terminal half-life (ti/2).
• Cmax maximum observed concentration
• tmax time to reach Cmax
• AUC clearance
• Vd apparent volume of distribution
• ti/2 terminal half-life
• Subjects in this study included adult subjects > 18 years of age with histologically or cytologically confirmed pancreatic adenocarcinoma.
• Subjects with previously untreated metastatic PD AC (1L metastatic PD AC) were enrolled in Cohort A.
• Subjects with metastatic PD AC previously treated with gemcitabine-based chemotherapy without exposure to 5-FU, capecitabine, or oxaliplatin [if considered a line of therapy]; 2L metastatic PD AC) were enrolled in Cohort B.
• Dose escalation began with enrollment of at least 3 subjects (and up to 6 subjects) at dose level 1 (1500 mg IV Q2W x 4 then Q4W). Subjects were monitored for DLTs. If no DLTs were observed in a cohort of 3 to 6 evaluable subjects, then dose escalation to the next higher dose cohort was permitted after review of all available safety data. If 1 subject in a dose-level cohort of 3 or more evaluable subjects experiences a DLT, that dose-level cohort was expanded to a total of 6 subjects. If no more than 1 of 6 subjects in the dose-level cohort experiences a DLT, dose escalation continued to the next higher dose-level cohort.
• Cohort A • Oleclumab at one of 3 dose levels (750 mg, 1500 mg, or 3000 mg) IV Q2W for 4 doses, then every 4 weeks (Q4W) and
• Part 2 dose expansion proceedsed as outlined in Figure 21.
• the RP2D of oleclumab identified in Part 1 for each regimen was evaluated with or without durvalumab in combination with chemotherapy.
• IHC immunohistochemistry
• Subjects in Cohort A (1L metastatic PD AC) were randomized 1 : 1 : 1 to one of 3 treatment arms: gemcitabine and nab- paclitaxel (Arm Al); oleclumab + gemcitabine and nab-paclitaxel (Arm A2); or oleclumab + durvalumab + gemcitabine and nab-paclitaxel (Arm A3).
• Subjects in Cohort B (2L metastatic PD AC) will be randomized 1 : 1 : 1 to one of 3 treatment arms: mFOLFOX (Arm Bl); oleclumab + mFOLFOX (Arm B2); or oleclumab + durvalumab + mFOLFOX (Arm B3). There was no crossover between treatment arms.
• the dose level for oleclumab was determined during Part 1 (dose escalation). As shown in Figures 22 and 23 and outlined below, subjects in Cohorts A and B were randomized to receive the treatments as follows:
• Example 6 Oleclumab and Durvalumab Treatment with or without Chemotherapy in Subjects with First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC)
• NSCLC Non-Small Cell Lung Cancer
• Subjects in this study include adult subjects > 18 years of age with histologically or cytologically documented Stage IV NSCLC not amendable to curative surgery or radiation with tumors lacking activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.
• Subjects have no prior chemotherapy or any other systemic therapy for Stage IV NSCLC. All subjects are required to have a World Health Organization (WHO)/ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment and treatment assignment.
• Subjects have no prior exposure to immune- mediated therapy including, excluding therapeutic anti-cancer vaccines.
• Subjects were excluded from participation in the study if they received any prior chemotherapy or any other systemic therapy for Stage IV NSCLC; if they are receiving any concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment; of if they received or are receiving any immunosuppressive medication within 28 days before the first
• Subjects are also excluded if they received radiation therapy unless it was (i) definitive radiation that had been administered at least 12 months prior to the date of progression to Stage IV disease, (ii) palliative radiation to brain, with associated criteria for stability or lack of symptoms, at least 4 weeks prior to the first study treatment dose, or (iii) palliative radiation to painful bony lesions (must comprise less than 30% of bone marrow) at least 2 weeks prior to the first study treatment dose.
• At least 30 patients were enrolled in each treatment arm as provided in Table 2 and shown in Figures 24A-24D.
• Patients with high-PD-Ll i.e., PD-L1 expression on >50% of tumor cells
• patients with and low PD-L1 i.e., PD-L1 expression on ⁇ 50% of tumor cells
• Chemotherapy is selected from: (a) nab-paclitaxel + carboplatin ((squamous and non- squamous patients); (b) gemcitabine + cisplatin (squamous patients only); (c) gemcitabine + carboplatin (squamous patients only); (d) pemetrexed + carboplatin (non-squamous patients only), and (e) pemetrexed + cisplatin (non-squamous patients only).
• Non-squamous patients who receive carboplatin/cisplatin + pemetrexed and who progress after 4 cycles of
• carboplatin/ cisplatin + pemetrexed receive pemetrexed maintenance therapy, unless
• pemetrexed maintenance therapy can be given either every three weeks (q3w) or every four weeks (q4w).
• Pemetrexed maintenance therapy can be given q4w for Arm B3.
• Treatment continues until clinical progression or radiological progression occur.
• chemotherapy were administered for 4 cycles or until progression of disease (PD) is observed, whichever occurs sooner (i.e., 4 cycles unless PD occurs prior to completion of the planned therapy).
• Example 7 Oleclumab and Durvalumab Treatment in Subjects with Locally Advanced, Unresectable, Stage PI Non-Small Cell Lung Cancer
• Subjects in this study included adult subjects at least 18 years of age (with a body weight of at least 35 kg) with locally advanced, unresectable, stage III NSCLC who have not progressed following definitive concurrent chemoradiotherapy (cCRT).
• Definitive radiotherapy refers to a total dose of > 60 Gy at 1.8 Gy per fraction or bioequivalent dose.
• Concurrent chemotherapy refers to a platinum-based doublet. The final chemotherapy administration must end prior to, or concurrently with, the final dose of radiation.
• Subjects were excluded from participation in the study if they had mixed small cell and non-small cell lung cancer histology. Subjects were also excluded from the study for use of immunosuppressive medications within 14 days before the first dose of study drug other than (i) intranasal, inhaled, or topical steroids, or local steroid injections (ii) systemic corticosteroids at physiologic doses note to exceed 10 mg/day of prednisone or its equivalent; and (iii) steroids as pre-medication for hypersensitivity reactions. Subjects were also excluded for any prior exposure to anti-PD-1, anti-PD-Ll or anti- cytotoxic T-lymphocyte associated antigen-4 (CTLA- 4) antibody for the treatment of NSCLC.
• CTLA- 4 cytotoxic T-lymphocyte associated antigen-4
• Subjects were treated for up to 12 months, unless disease progression, unacceptable toxicity, or another reason (e.g., subject decision or noncompliance) for termination of treatment occur ed.
• Example 8 Oleclumab and Durvalumab Treatment in Subjects with Resectable, Early- Stage Non-Small Cell Lung Cancer
• Subjects in this study included adult subjects at least 18 years of age (with a body weight of at least 35 kg) with cytologically and/or histologically documented NSCLC that was (a) Stage I (> 2 cm) to IIIA (for subjects with N2 disease, only those with 1 single nodal station ⁇ 3 cm were eligible) NSCLC according to the 8 th edition of American Joint Committee on Cancer staging classification; and (b) considered amenable to complete surgical resection. The subjects had not received any other therapy (chemotherapy, biologic, or radiotherapy) for this condition. All subjects had an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• chemotherapy chemotherapy, biologic, or radiotherapy
• Subjects were excluded from participation in the study if they had mixed small cell and non-small cell lung cancer histology. Subjects were also excluded from the study as a result of participation in another interventional clinical study within 90 days prior to enrollment.
• Subjects were also excluded from the study for use of immunosuppressive medications within 14 days before the first dose of study drug other than (i) intranasal, inhaled, or topical steroids, or local steroid injections (ii) systemic corticosteroids at physiologic doses note to exceed 12 mg/day of prednisone or its equivalent; and (iii) steroids as pre-medication for hypersensitivity reactions.
• Fig. 26A The treatment over the course of the study duration period is shown in Fig. 26A.
• Subjects were treated with either durvalumab monotherapy or a combination of durvalumab and oleclumab for up to 28 days. Treatment was discontinued upon disease progression, unacceptable toxicity, or another reason (e.g., subject decision or noncompliance).
• Subjects who received durvalumab monotherapy received 1500 mg durvalumab intravenously Q4W on Week 1, Day 1.
• Fig. 26B. Subjects who received combination therapy received 1500 mg durvalumab intravenously Q4W on Week 1, Day 1, plus 3000 mg oleclumab intravenously Q2W on Week 1, Day 1, and Week 3, Day 1.
• Fig. 26C. the treatment over the course of the study duration period is shown in Fig. 26A. Subjects were treated with either durvalumab monotherapy or a combination of durvalumab and oleclumab for up to 28 days. Treatment was discontinued upon disease progression,
• the 28-day treatment period was followed by surgical resection.
• the surgical resection was within 14 days of the treatment period. After surgical resection, subjects were followed up to Day 105. If a subject received adjuvant chemotherapy or radiotherapy prior to Day 105, the subject came off study, and the end of study visit was scheduled prior to the start of adjuvant therapy.
• Pathological changes e.g., major pathologic responses (MPRs)
• MPRs major pathologic responses
• pCR pathological complete response
• BOR best overall response
• ORR per RECIST v 1.1 are also evaluated to demonstrate that the combination of oleclumab and durvalumab has antitumor activity in resectable, early-stage NSCLC.
• Adverse events, laboratory findings, and vital signs are assessed to demonstrate that the combination of oleclumab and durvalumab is safe.
• a Phase lb/2 open-label, multicenter study was performed to assess the efficacy (antitumor activity) and safety of oleclumab and durvalumab in combination with chemotherapy and bevacizumab as a first-line (1L) therapy in subjects with metastatic microsatellite-stable colorectal cancer (MSS-CRC).
• the study included two parts. Part 1 was a Phase lb safety study, and Part 2 was a Phase 2 study of efficacy and safety.
• Subjects in this study included adult subjects at least 18 years of age (with a body weight of at least 35 kg) with metastatic MSS-CRC who had not received prior systemic treatment in the recurrent/metastatic setting (subjects treated with prior adjuvant chemotherapy or radio-chemotherapy were accepted as long as progression was not within 6 months of completing the adjuvant regimen). All subject had histological documentation of advanced or metastatic CRC and a documented mutation test during screening and confirmed tumor locations from disease assessment. Subjects must not have had defective DNA mismatch repair (MSI) as document by testing.
• MSI defective DNA mismatch repair
• Subjects had at least one lesion that was measurable by RECIST vl .1 (a previously irradiated lesion could be considered a target legion if the lesion was well defined, measurable per RECIST, and had clearly progressed during or after the most recent therapy). All subjects had an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• ECOG Eastern Cooperative Oncology Group
• Subjects were excluded from the study as a result of any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment (concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) was acceptable.
• Subjects were also excluded from the study for radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to the scheduled first dose of study treatment.
• Subjects were also excluded for prior receipt of any immune- mediated therapy or anti-angiogeneics.
• Subjects were also excluded from the study for use of immunosuppressive medications within 14 days before the first dose of study drug other than (i) intranasal, inhaled, or topical steroids, or local steroid injections and (ii) steroids as pre medication for hypersensitivity reactions.
• Part 1 Following a screening period of up to 28 days, subjects were assigned (Part 1) or randomized (Part 2) to a study arm. In both study parts, treatment was administered until disease progression or any discontinuation criteria (e.g., withdraw of consent, unacceptable toxicity, noncompliance, confirmed progressive disease, etc.) were met.
• discontinuation criteria e.g., withdraw of consent, unacceptable toxicity, noncompliance, confirmed progressive disease, etc.
• Part 1 did not involve dose escalation.
• An initial group of 3 subjects was enrolled into Part 1 arms and evaluated for safety. Decisions in Part 1 were based on rules adapted from the modified toxicity probability interval-2 (mTPI-2) algorithm (Guo et al., Contemp Clin Trials 58: 23-33 (2017)), which employed a simple beta-binomial Bayesian model. If the decision rule was to“stay” for the first 3 subjects, then an additional group of 2-4 subjects was enrolled at the same dose level; if the decision rule was to“de-escalate,” an additional group of 3 subjects were enrolled to a lower dose of oleclumab while maintaining the standard dose of FOLFOX plus bevacizumab plus durvalumab. If the decision rule was“completion,” the current dose was selected for Part 2 of the study.
• mTPI-2 modified toxicity probability interval-2
• the treatment groups are provided in Table 5, and the treatment schedules s are provided in Fig. 27.
• Folinic acid (leucovorin) + 5-fluorouracil + oxaliplatin (FOLFOX) plus bevacizumab were administered as outlined in the protocol per National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) guidelines.
• 400 mg/m 2 of folinic acid was administered intravenously every 2 weeks (Q2W) (Day 1 of every 14- day cycle); 85 mg/m 2 of oxaliplatin was administered by intravenous infusion Q2W (Day 1 of every 14-day cycle); and 2400 mg/m 2 of 5-fluorouracil was administered by continuous intravenous infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle).
• 5-Fluorouracil was administered as infusion only, with no bolus.
• 5 mg/kg of bevacizumab was administered by intravenous infusion Q2W (Day 1 of every 14-day cycle).
• the objective response per RECIST v 1.1 is evaluated to demonstrate that the combination of oleclumab and durvalumab with FOLFOX plus bevacizumab has superior antitumor activity to FOLFOX with bevacizumab in subjects with 1L MSS-CRC.
• Best overall response BOR
• DoR duration of response
• DC disease control
• PFS-12 12-month progression free survival
• PFS progression free survival
• OS overall survival
• Example 10 Oleclumab and Durvalumab in Combination with Adjuvant Chemotherapy Treatment in Subjects with High-Risk Metastatic Microsatellite-Stable Colorectal Cancer
• Subjects in this study included adult subjects at least 18 years of age (with a body weight of at least 35 kg) who had undergone radical surgical resection for Stage II or III MSS- CRC, were eligible for 6 months of mFOLFOX6 adjuvant therapy within 8 weeks after surgery, and were confirmed as having circulating tumor DNA (ctDNA) positive post-surgery. All subjects were required to be high risk Stage P: any T4 lesion or a T3 lesion with any one of the following characteristics: high grade (3), clinical presentation with bowel obstruction and perforation, histological signs of vascular, lymphatic and perineural invasion, ⁇ 12 lymph nodes examined.
• Subjects must not have received prior systemic chemotherapy, immunotherapy, or radiotherapy for treatment of colorectal cancer (CRC) and must not have defective DNA mismatch repair (MSI).
• Subjects had a margin-negative (R0; defined as > 1 mm clearance) surgical resection. All subjects had an Eastern Cooperative Oncology Group (ECOG)
• Subjects were excluded from the study if there was evidence of metastatic disease (including the presence of tumor cells in ascites or peritoneal carcinomatosis resected“en bloc”). Subjects were also excluded for concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. Subjects were also excluded from the study for use of immunosuppressive medications within 14 days before the first dose of study drug other than (i) intranasal, inhaled, or topical steroids, or local steroid injections and (ii) steroids as pre medication for hypersensitivity reactions.
• Subjects were randomized to one of the study arms. Approximately 40 subjects per treatment arm were enrolled. Randomization was strategized by the American Joint Committee on Cancer stage of the primary tumor (Stage II vs Stage III). The study arms and treatments are summarized in Table 6, and the dosing regimens are provided in Fig. 28.
• mFOLFOX6 folinic acid (leucovorin), 5-fluorouracil, oxaliplatin [00287]
• mFOLFOX6 folinic acid (leucovorin), 5-fluorouracil, oxaliplatin
• Q2W 2 weeks
• oxaliplatin was administered at a dose of 85 mg/m 2 by intravenous (IV) infusion (Day 1 of every 14-day cycle) limited to a maximum body surface area (BSA) of 2.0 m 2 .
• BSA body surface area
• Folinic acid (leucovorin) was administered at a dose of 400 mg/m 2 by IV infusion (Day 1 of every 14-day cycle).
• Fluorouracil (5-FU) was administered at a dose of 400 mg/m 2 by IV bolus on Day 1, then 1,200 mg/m 2 /day for 2 days (total 2,400 mg/m 2 over 46-48 hours) IV infusion (Days 1-2 of every 14-day cycle).
• Durvalumab was administered at a dose of 1500 mg IV every 4 weeks (Q4W), and oleclumab was administered at a dose of 3000 mg IV Q2W for four doses then Q4W starting at Cycle 5.
• Subjects were treated for up to 6 months or until recurrence, unacceptable toxicity, withdrawal of consent, etc. Subjects could be followed for up to 5 years from randomization.
• CtDNA clearance is defined as the ctDNA status change from ctDNA positive at baseline to ctDNA negative post-randomization, and comparison between groups is performed using the Cochran-Matnel-Haenszel test stratified by the disease stage at a significance level of 0.2 (2- sided).
• mice were implanted subcutaneously with murine syngeneic tumour lines, either 0.5e6 CT26 (mouse colorectal) or 0.5e6 MCA205 (50% Matrigel) (mouse fibrosarcoma) depending on mouse strain. Tumour progression was monitored by caliper measurements 3 times a week.
• the animals were treated (as monotherapy or in different combinations) with anti-CD73 mouse IgGl (in house, AstraZeneca) starting on day 3, 10 mg/kg, twice weekly, 4 doses; anti- PD-U1 mouse IgGl D265A (in house, AstraZeneca) starting on day 10 (when combined with OHP and 5FU) or 4 (when combined with Docetaxel), 10 mg/kg, twice weekly up-to a total of 6 doses (see figure legends for information concerning specific experiments); 5-fluorouracil (Fresenius Kabi) and oxaliplatin (Accord) on day 9 (or day 10 in some experiments), single dose, 50 mg/kg and 6 mg/kg; Docetaxel (Sanofi), starting on day 4, lOmg/kg, once weekly, 2 doses, respectively.
• the two antibodies, plus 5FU and OHP were administered intraperitoneally, while Docetaxel was administered intravenously.
• the animals were humanely sacrificed once the tumor
• the animals were implanted with 0.5e6 CT26 mouse colorectal carcinoma cells subcutaneously. Tumour progression was monitored by caliper measurements 3 times a week.
• the animals were treated (as monotherapy or in different combinations) with anti-CD73 mouse IgGl (in house, AstraZeneca) starting on day 3, 10 mg/kg, twice weekly, 4 doses; anti-PD-Ul mouse IgGl D265A (in house, AstraZeneca) starting on day 10, 10 mg/kg, twice weekly, 2 doses; 5-fluorouracil (Fresenius Kabi) and oxaliplatin (Accord), on day 10, single dose, 50 mg/kg and 6 mg/kg, respectively. All drugs were administered intraperitoneally. The animals were humanely sacrificed on day 15 post implantation and the tumours were used in downstream analyses.
• tumours were digested using an enzyme cocktail of 1 mg/mL collagenase IV, 20 units/mL DNase I and 20 units/mL hyaluronidase I (all from Sigma).
• the single cell suspension was then stained with a live/dead differentiating dye (see table 7 below) and treated with Pc block (anti-mouse CD16/CD32 eBioScience cat # 14-0161-86).
• the cells were stained for surface markers (for reagent list see table & below) and fixed and permeabilised using the eBioScience Poxp3/transcription factor staining kit (00-5523-00).
• the cells were stained for intracellular markers (see table 7 below).
• the samples were acquired on a BD Symphony flow cytometer and analysed using PlowJo software version 10. The data was plotted using the GraphPad Prizm software.
• Fig. 30 presents data from whole tumor digests (samples collected on day 15 post implantation) analysed by flow cytometry without ex vivo re-stimulation
• mice implanted with CT26 tumours the combination of anti-PD-Ll + anti-CD73 + 5FU + OHP resulted in 6 out of 12 (50%) complete responses compared to maximum of 2 out of 12 ( ⁇ 17%) in the anti-PD-Ll + 5FU + OHP combination group.
• the combination of anti-PD-Ll + anti-CD73 + docetaxel resulted in 7 out of 12 (58%) complete responses compared to maximum of 3 out of 12 (25%) in the anti-PD-Ll + docetaxel combination group.
• TME tumour microenvironment
• mice implanted with MCA205 tumours the combination of anti-PD-Ll + anti- CD73 + 5FU + OHP results in 8 out of 13 (61%) complete responses compared to 4 out of 13 (30%) in the anti-PD-Ll + 5FU + OHP combination group.
• anti-CD73 antibodies increase the efficacy of anti-PD-Ll plus chemotherapy (including e.g., 5FU+OHP and docetaxel) treatments, in multiple cancer types.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Biochemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Inorganic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=72663659

Family Applications (1)

Country Status (13)

Cited By (3)

Families Citing this family (2)

Citations (3)

Family Cites Families (4)

• 2020
  • 2020-04-01 US US16/837,477 patent/US20200317803A1/en not_active Abandoned
  • 2020-04-01 KR KR1020217035422A patent/KR20210148253A/ko active Pending
  • 2020-04-01 JP JP2021558768A patent/JP2022527334A/ja active Pending
  • 2020-04-01 WO PCT/IB2020/053110 patent/WO2020202038A1/en not_active Ceased
  • 2020-04-01 CN CN202080039845.5A patent/CN113993890A/zh active Pending
  • 2020-04-01 TW TW109111394A patent/TW202102545A/zh unknown
  • 2020-04-01 EA EA202192587A patent/EA202192587A1/ru unknown
  • 2020-04-01 CN CN202510064168.7A patent/CN119857140A/zh active Pending
  • 2020-04-01 CA CA3134671A patent/CA3134671A1/en active Pending
  • 2020-04-01 AU AU2020254100A patent/AU2020254100B9/en active Active
  • 2020-04-01 MA MA055558A patent/MA55558A/fr unknown
  • 2020-04-01 EP EP20783214.8A patent/EP3947447A4/en not_active Withdrawn
  • 2020-04-01 SG SG11202110694RA patent/SG11202110694RA/en unknown
• 2021
  • 2021-09-19 IL IL286504A patent/IL286504A/en unknown
• 2025
  • 2025-01-06 AU AU2025200063A patent/AU2025200063A1/en active Pending
  • 2025-10-02 JP JP2025166226A patent/JP2026031542A/ja active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events